

Sarah C Glover

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7132792/publications.pdf>

Version: 2024-02-01

79
papers

2,112
citations

331670

21
h-index

243625

44
g-index

83
all docs

83
docs citations

83
times ranked

3899
citing authors

#	ARTICLE	IF	CITATIONS
1	The Current State of Care for Black and Hispanic Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 297-307.	1.9	6
2	OUP accepted manuscript. <i>Gastroenterology Report</i> , 2022, 10, goab041.	1.3	1
3	Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1010-1017.e10.	2.9	38
4	Urinary manifestations in African American and Caucasian inflammatory bowel disease patients: a retrospective cohort study. <i>BMC Urology</i> , 2022, 22, 1.	1.4	8
5	Hereditary alpha-tryptasemia despite normal tryptase-encoding gene copy number owing to copy number loss in trans. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 460-461.	1.0	4
6	Clinical Manifestations of Copper Deficiency: A Case Report and Review of the Literature. <i>Nutrition in Clinical Practice</i> , 2021, 36, 1080-1085.	2.4	11
7	Examination of gene expression in saliva samples from COVID-19 patients to study the host defense response against SARS-CoV-2 in the oral cavity. <i>Molecular Oral Microbiology</i> , 2021, 36, 157-158.	2.7	6
8	Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 677-685.	1.9	5
9	The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort. <i>Gut Microbes</i> , 2021, 13, 1-15.	9.8	46
10	Distinct Small Intestine Mast Cell Histologic Changes in Patients With Hereditary Alpha-tryptasemia and Mast Cell Activation Syndrome. <i>American Journal of Surgical Pathology</i> , 2021, 45, 997-1004.	3.7	24
11	Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy. <i>American Journal of Gastroenterology</i> , 2021, 116, 1638-1645.	0.4	12
12	A humanized monoclonal antibody against the endothelial chemokine CCL21 for the diagnosis and treatment of inflammatory bowel disease. <i>PLoS ONE</i> , 2021, 16, e0252805.	2.5	3
13	The Impact of Transition Readiness and Stress on Patient-Centered Outcomes in Young Adults With Inflammatory Bowel Disease. <i>Gastroenterology Nursing</i> , 2021, 44, 259-267.	0.4	1
14	Clinical relevance of inherited genetic differences in human tryptases. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 638-647.	1.0	30
15	Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. <i>Cell</i> , 2021, 184, 4713-4733.e22.	28.9	206
16	Small intestinal immunopathology and GI-associated antibody formation in hereditary alpha-tryptasemia. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 813-821.e7.	2.9	17
17	Failure to thrive: A severe manifestation of interleukin 10 receptor A mutation in adult inflammatory bowel disease. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, , .	2.6	2
18	Response to Cheng et al.. <i>American Journal of Gastroenterology</i> , 2021, Publish Ahead of Print, .	0.4	0

#	ARTICLE	IF	CITATIONS
19	A Spy took a bite to get the diagnosis right: the benefit of SpyGlass technology in the diagnosis of autoimmune pancreatitis evading traditional diagnostic methods. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000694.	2.7	0
20	Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1554-1561.	1.9	12
21	MyD88 regulates a prolonged adaptation response to environmental dust exposure-induced lung disease. <i>Respiratory Research</i> , 2020, 21, 97.	3.6	11
22	STAT3 Genotypic Variant rs744166 and Increased Tyrosine Phosphorylation of STAT3 in IL-23 Responsive Innate Lymphoid Cells during Pathogenesis of Crohn's Disease. <i>Journal of Immunology Research</i> , 2019, 2019, 1-10.	2.2	9
23	Lipidomic analysis of urinary exosomes from hereditary α_1 -antitrypsinemia patients and healthy volunteers. <i>FASEB BioAdvances</i> , 2019, 1, 624-638.	2.4	21
24	Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1417-1427.	1.9	89
25	P087 ILEAL BIOMARKER OF INNATE IMMUNE ACTIVATION CAN PREDICT CLINICAL RESPONSE TO VEDOLIZUMAB IN CROHN'S DISEASE. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S41-S41.	1.9	4
26	Treatment-resistant eosinophilic oesophagitis successfully managed with tofacitinib. <i>BMJ Case Reports</i> , 2019, 12, e232558.	0.5	16
27	Small Bowel Pyogenic Granuloma With Cytomegalovirus Infection in a Patient With Crohn's Disease (Report of a Case and Review of the Literature). <i>In Vivo</i> , 2019, 33, 251-254.	1.3	2
28	Pre-operative total parenteral nutrition improves post-operative outcomes in a subset of Crohn's disease patients undergoing major abdominal surgery. <i>Gastroenterology Report</i> , 2019, 7, 107-114.	1.3	20
29	Effects of Preoperative Use of Biologic Agents on Operative Outcomes in Crohn's Disease Patients. <i>American Surgeon</i> , 2018, 84, 1526-1530.	0.8	2
30	Perioperative Care of Patients with Inflammatory Bowel Disease: Focus on Nutritional Support. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-13.	1.5	24
31	Innate Lymphoid Cells in Inflammatory Bowel Disease. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 415-421.	2.3	15
32	Incorporation of Scribes Into the Inflammatory Bowel Disease Clinic Improves Quality of Care and Physician Productivity. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 552-557.	1.9	9
33	Quantitative assessment of intestinal stiffness and associations with fibrosis in human inflammatory bowel disease. <i>PLoS ONE</i> , 2018, 13, e0200377.	2.5	53
34	Effects of Preoperative Use of Biologic Agents on Operative Outcomes in Crohn's Disease Patients. <i>American Surgeon</i> , 2018, 84, 1526-1530.	0.8	2
35	Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, E17.	1.9	32
36	Complete resolution of severe ulcerative colitis after haploidentical hematopoietic stem cell transplantation followed by post-transplant high-dose cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2017, 52, 1204-1205.	2.4	2

#	ARTICLE	IF	CITATIONS
37	Enrichment of IL-17A+ IFN- γ + and IL-22+ IFN- γ + T cell subsets is associated with reduction of Nkp44+ ILC3s in the terminal ileum of Crohn's disease patients. Clinical and Experimental Immunology, 2017, 190, 143-153.	2.6	32
38	Successful targeted treatment of mast cell activation syndrome with tofacitinib. European Journal of Haematology, 2017, 99, 190-193.	2.2	10
39	Enhanced TH17 Responses in Patients with IL10 Receptor Deficiency and Infantile-onset IBD. Inflammatory Bowel Diseases, 2017, 23, 1950-1961.	1.9	28
40	Increased Mucosal IL-22 Production of an IL-10RA Mutation Patient Following Anakinra Treatment Suggests Further Mechanism for Mucosal Healing. Journal of Clinical Immunology, 2017, 37, 104-107.	3.8	8
41	Vedolizumab: a novel medical intervention in the treatment of primary sclerosing cholangitis. BMJ Case Reports, 2017, 2017, bcr-2017-220351.	0.5	5
42	Oesophageal mastocytosis: eosinophilic oesophagitis without eosinophils?. BMJ Case Reports, 2017, 2017, bcr-2017-221276.	0.5	1
43	Coming full circle: an impressive case of Crohn's disease. BMJ Case Reports, 2016, 2016, bcr2015214132.	0.5	0
44	Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF- α Therapy With Infliximab for Crohn's Disease. ACG Case Reports Journal, 2016, 3, 187-189.	0.4	9
45	The differential frequency of Lineage α^+ CRTH2 α^+ CD45+Nkp44 α^+ CD117 α^+ CD127+ILC subset in the inflamed terminal ileum of patients with Crohn's disease. Cellular Immunology, 2016, 304-305, 63-68.	3.0	27
46	Interleukin 1 β Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency. Gastroenterology, 2016, 151, 1100-1104.	1.3	156
47	Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nature Genetics, 2016, 48, 1564-1569.	21.4	279
48	Tofacitinib for the treatment of tumor necrosis factor- α inhibitor refractory esophageal Crohn's disease: a case report. Journal of Medical Case Reports, 2016, 10, 264.	0.8	1
49	Intestinal Epithelial Cell Regulation of Adaptive Immune Dysfunction in Human Type 1 Diabetes. Frontiers in Immunology, 2016, 7, 679.	4.8	11
50	Aryl hydrocarbon receptor signaling involves in the human intestinal ILC3/ILC1 conversion in the inflamed terminal ileum of Crohn's disease patients. Inflammation and Cell Signaling, 2016, 3, .	1.6	21
51	ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Survival in Colorectal Cancer. Anticancer Research, 2015, 35, 3267-73.	1.1	6
52	Febrile pleuropéricarditis, a potentially life-threatening adverse event of balsalazide â€“ case report and literature review of the side effects of 5-aminosalicylates. Expert Review of Clinical Immunology, 2014, 10, 667-675.	3.0	9
53	Sa1916 Increased Expression of ROCK I and Met in Colorectal Cancer Is Associated With Decreased Patient Survival. Gastroenterology, 2014, 146, S-328.	1.3	0
54	Evaluation Of Antigenic Triggers and Etiologies In Eosinophilic Esophagitis: A Single Center Experience. Journal of Allergy and Clinical Immunology, 2014, 133, AB261.	2.9	0

#	ARTICLE	IF	CITATIONS
55	Placental Transfer of Anti-“Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 286-292.	4.4	420
56	Influence of host immunoregulatory genes, ER stress and gut microbiota on the shared pathogenesis of inflammatory bowel disease and Type 1 diabetes. <i>Immunotherapy</i> , 2013, 5, 1357-1366.	2.0	23
57	Tumor Stiffness Is Unrelated to Myosin Light Chain Phosphorylation in Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e79776.	2.5	7
58	Treatment with Y-27632, a ROCK Inhibitor, Increases the Proinvasive Nature of SW620 Cells on 3D Collagen Type 1 Matrix. <i>International Journal of Cell Biology</i> , 2012, 2012, 1-7.	2.5	22
59	Higher Molecular Weight Polyethylene Glycol Increases Cell Proliferation While Improving Barrier Function in an In Vitro Colon Cancer Model. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-7.	3.0	17
60	The extracellular matrix microtopography drives critical changes in cellular motility and Rho A activity in colon cancer cells. <i>Cancer Cell International</i> , 2010, 10, 24.	4.1	6
61	T1750 In Vitro and In Vivo Evidence in Support of Differentiation of Colon Cancer Stem Cells Into Adipocyte-Like Cells. <i>Gastroenterology</i> , 2010, 138, S-570.	1.3	0
62	W1769 Colon Cancer and Rho Kinase: Is Rock-II Really the Most Active Rock?. <i>Gastroenterology</i> , 2010, 138, S-736.	1.3	0
63	S2056 Polyethylene Glycol (PEG) Prevents Against the Pro-Invasive Effects of Both Commensal and Pathogenic E. coli and May Increase Chemosensitiveness of Colon Cancer Cells By Increasing Proliferation. <i>Gastroenterology</i> , 2009, 136, A-321.	1.3	0
64	S1883 To Biopsy or Not to Biopsy in Chronic Constipation? a Possible Role for Eosinophils in This Irritating Condition. <i>Gastroenterology</i> , 2009, 136, A-284.	1.3	0
65	T1754 Commensal E. coli Strains Have the Ability to Alter the ECM Topography Independent of Colonic Epithelial Cells. <i>Gastroenterology</i> , 2009, 136, A-573.	1.3	0
66	S2057 A Loss of Symbiosis with Certain Strains of Commensal E Coli Leads to Increased Colon Cancer Invasion in An In Vitro Colon Cancer Model Via Activation of Rac and MMP-1. <i>Gastroenterology</i> , 2008, 134, A-306.	1.3	0
67	S2007 Bacterial Microbiota Fingerprints Are Altered in Colon Cancer. <i>Gastroenterology</i> , 2008, 134, A-296.	1.3	0
68	ROCK-II mediates colon cancer invasion via regulation of MMP-2 and MMP-13 at the site of invadopodia as revealed by multiphoton imaging. <i>Laboratory Investigation</i> , 2007, 87, 1149-1158.	3.7	81
69	Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, G718-G728.	3.4	41
70	Transient upregulation of GRP and its receptor critically regulate colon cancer cell motility during remodeling. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, G1274-G1282.	3.4	16
71	Phosphorylation of focal adhesion kinase tyrosine 397 critically mediates gastrin-releasing peptide's morphogenic properties. <i>Journal of Cellular Physiology</i> , 2004, 199, 77-88.	4.1	25
72	Increased frequency of gastrin-releasing peptide receptor gene mutations during colon-adenocarcinoma progression. <i>Molecular Carcinogenesis</i> , 2003, 37, 5-15.	2.7	28

#	ARTICLE	IF	CITATIONS
73	Expression of Grp and its receptor in well differentiated human colon cancer cells correlates with the presence of focal adhesion kinase phosphorylated at tyrosines 397 and 407. Gastroenterology, 2003, 124, A610.	1.3	2
74	FAK phosphorylation at Y397 mediates GRP's morphogenic properties of enhancing cell attachment and promoting tissue remodeling. Gastroenterology, 2003, 124, A23.	1.3	0
75	Caco-2 cell remodeling is regulated by transient up-regulation of gastrin-releasing peptide (GRP) and its receptor (GRPR). Gastroenterology, 2003, 124, A100.	1.3	1
76	GRP receptor-induced phosphorylation of FAK-Y397 decreases cell distensibility and blebbing. Gastroenterology, 2003, 124, A602.	1.3	0
77	Expression of GRP and Its Receptor in Well-differentiated Colon Cancer Cells Correlates with the Presence of Focal Adhesion Kinase Phosphorylated at Tyrosines 397 and 407. Journal of Histochemistry and Cytochemistry, 2003, 51, 1041-1048.	2.5	52
78	Pharmacologically inactivating mutations in the GRPR gene increase in frequency as human colon cancers de-differentiate. Gastroenterology, 2001, 120, A60-A61.	1.3	0
79	Method for and characterization of proteins isolated by laser capture microdissection from formalin-fixed, paraffin-embedded tumors. Gastroenterology, 2001, 120, A170.	1.3	0